VSA 012
Alternative Names: VSA-012Latest Information Update: 12 Feb 2026
At a glance
- Originator Visirna Therapeutics
- Class Small interfering RNA
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 06 Dec 2025 Phase-I clinical trials in Paroxysmal nocturnal haemoglobinuria (Treatment-naive) in China (SC) (NCT06848296)
- 06 Dec 2025 Interim adverse event, pharmacodynamic and efficacy data from a phase Ib trial in Paroxysmal nocturnal hemoglobinuria presented at the at the 67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)
- 27 Feb 2025 Visirna Therapeutics plans to initiate a phase Ib trial for Paroxysmal Nocturnal Hemoglobinuria (NCT06848296)